We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sanofi Sa | LSE:0A2V | London | Ordinary Share | SANOFI ADR REP 1 1/2 ORD (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 328 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 43.07B | 5.4B | 4.2694 | 21.38 | 0 |
TIDMTTM TIDM0A2V
RNS Number : 3083I
Threadneedle Asset Mgmt Hldgs Ltd
01 December 2022
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION Threadneedle Asset Management Holdings Ltd (on behalf of affiliate companies that carry on (a) Full name of discloser the business of fund and portfolio management) (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is Ameriprise Financial, Inc. ultimate parent company of insufficient. For a trust, the trustee(s), Threadneedle Asset Management Holdings settlor and beneficiaries must be named. Ltd and affiliated companies. ---------------------------------------------------------- (c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree Horizon Therapeutics plc ---------------------------------------------------------- (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) ---------------------------------------------------------- (e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure 29(th) November 2022 ---------------------------------------------------------- (f) In addition to the company in 1(c) above, is No the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" ---------------------------------------------------------- 2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) $0.0001 ordinary shares Interests Short positions ------------------ ----------------- Number % Number % ----------- ----- ------------- (1) Relevant securities owned and/or controlled 2,529,983 1.12 ----------- ----- ------------- (2) Cash-settled derivatives ----------- ----- ------------- (3) Stock-settled derivatives (including options) and agreements to purchase/ sell ----------- ----- ------------- Total 2,529,983 1.12 ----------- ----- -------------
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales Class of relevant Purchase/sale Number of Price per unit security securities (Note 5) $0.0001 ordinary shares Sale 42 USD 78.76 -------------- ------------ --------------- $0.0001 ordinary shares Purchase 255 USD 78.77 -------------- ------------ ---------------
Ap29
(b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price relevant description e.g. opening/ closing a long/ short position, increasing/ reference per unit security e.g. CFD reducing a long/ short position securities (Note 5) (Note 6) (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, purchasing, Number Exercise Type Expiry Option relevant description e.g. selling, varying of price per e.g. date money security call etc. securities unit American, paid/ option to which European received per unit option etc. relates (Note 6) (ii) Exercise Class of Product Exercising/ Number of Exercise relevant description exercised securities price per security e.g. call against unit option (Note 5) (d) Other dealings (including transactions in respect of new securities) (Note 3) Class of Nature of dealing Details Price per unit (if relevant e.g. subscription, applicable) security conversion, exercise (Note 5)
Ap30
4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b) Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. None (c) Attachments Is a Supplemental Form 8 attached? NO Date of disclosure 01/12/2022 Contact name Ben Lyon -------------- Telephone number +441793 363754 --------------
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ISEXFLFBLLLEFBD
(END) Dow Jones Newswires
December 01, 2022 09:02 ET (14:02 GMT)
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions